title: [Insomnia and cerebral hypoperfusion].
abstract: Insomnia is defined as difficulty with the initiation, maintenance, duration, or quality of sleep that results in the impairment of daytime functioning, despite adequate opportunity and circumstances for sleep. In most countries approximately every third inhabitant has insomnia. Insomnia can be classified as primary and secondary. The pathogenesis of primary insomnia is unknown, but available evidence suggests a state of hyperarousal. Insomnia secondary to other causes is more common than primary insomnia. Cerebral hypoperfusion can be the cause of insomnia in some cases. In such patients the cerebral blood flow should be improved using parenteral vascular therapy. If insomnia persists despite treatment, then therapy for primary insomnia should be instituted using benzodiazepine-receptor agonists such as Zolpidem, Zopiclone, or Zaleplon. In those cases Midazolam cannot be used for the treatment of insomnia due to its marked negative effect on cerebral blood flow. In Hungary there is a need to organize multidisciplinary Insomnia Clinics because insomnia is more than a disease, it is a public health problem in this century.
authors.affiliation: Fovárosi Onkormányzat Jahn Ferenc Dél-Pesti Kórház, Neurológiai Osztály, Budapest. kaposztaz@jahndelpest.hu
authors.forename: Zoltán
authors.initials: Z
authors.lastname: Káposzta
authors.forename: Klára
authors.initials: K
authors.lastname: Rácz
mesh_terms: D002560:Cerebrovascular Circulation / Q000187:drug effects; D058785:GABA-A Receptor Agonists; D006801:Humans; D006814:Hungary / Q000453:epidemiology; D002534:Hypoxia, Brain / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology; D007319:Sleep Initiation and Maintenance Disorders / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology* / Q000503:physiopathology*
chemical_list: D058785:GABA-A Receptor Agonists